Steven B. Engle is a Chief Executive Officer, Director of the Company. He joined CohBar as Chief Executive Officer in May 2019 and was appointed to our Board in July 2019. From September 2011 until May 2019, he served as the Chief Executive Officer of Averigon Consulting, an advisory firm providing business development, fundraising, operational and consultancy services to life science companies. From August 2007 to August 2011, Mr. Engle was Chairman, Chief Executive Officer and President of XOMA Corporation (NASDAQ: XOMA), a publicly-traded biotechnology company. Previously, he held multiple executive management roles at La Jolla Pharmaceutical Company (NASDAQ: LJPC), a publicly-traded biotechnology company, including serving as Chairman and Chief Executive Officer from 1997 to 2006, President and Chief Executive Officer from 1995 to 1997, and Executive Vice President and Chief Operating Officer from 1993 to 1994. Mr. Engle currently serves as Chairman of the board of directors of Prescient Therapeutics (ASX: PTX), and as a member of the board of directors at various private companies. Mr. Engle received his B.S. in Electrical Engineering and his M.S. in Electrical Engineering from the University of Texas, Austin. Mr. Engle’s industry experience, together with his experience serving on other companies’ boards, make him an important contributor to our Board.
As the Chief Executive Officer and Director of CohBar Inc, the total compensation of Steven Engle at CohBar Inc is $2,410,850. There are no executives at CohBar Inc getting paid more.
Steven Engle is 65, he's been the Chief Executive Officer and Director of CohBar Inc since 2019. There are 4 older and 8 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.
Steven's mailing address filed with the SEC is C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY, CA, 94710.
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy, and Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
CohBar Inc executives and other stock owners filed with the SEC include: